Healthcare Industry News: Johnson & Johnson
News Release - October 29, 2015
BioPharmX Corporation Names AnnaMarie Daniels Executive Vice President of Clinical and Regulatory AffairsLife science veteran brings 30 years of experience managing development through commercialization of breakthrough dermatology, pharmaceutical and medical device products
MENLO PARK, Calif., Oct. 29, 2015 -- (Healthcare Sales & Marketing Network) -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced the appointment of industry veteran AnnaMarie Daniels as its executive vice president of clinical and regulatory affairs.
In this role, Daniels will oversee the clinical and regulatory affairs programs globally and will be responsible for the management of clinical trials, protocol development, institutional review board submissions and interactions with regulatory agencies.
Daniels has worked with companies in Europe and the United States and has extensive experience with investigational new drugs, managing complex clinical trials and leading regulatory pathway strategies with the FDA and Global Regulatory Authorities.
"AnnaMarie provides insight and experience that will be critical as we pull products through our pipeline on an aggressive timetable," said Anja Krammer, president and co-founder of BioPharmX Corporation. "Her track record of bringing innovative, high-quality medical products to market efficiently and cost effectively complements the scientific and business expertise of our senior team."
Daniels previously led the botulinum neurotoxin program at Johnson & Johnson as well as the clinical research program for Boston Scientific Neuromodulation. Previously, she held several executive, technical and independent consulting level positions in a range of pharmaceutical and medical device companies including Target Therapeutics, Cervel Neurotech, ReVENT Medical and Merz Pharmaceuticals. In these roles, she was instrumental in the development and commercialization of new products, negotiating significant agreements with major pharmaceutical partners and generating millions of dollars in income.
"I was drawn to BioPharmX because the product pipeline is rich with opportunity," said AnnaMarie Daniels. "The company's novel wellness products address unmet healthcare needs in women's health and dermatology, and I look forward to leading the transformation of these products from the R&D stage to commercialization."
In connection with her appointment as executive vice president of clinical and regulatory affairs, the compensation committee of BioPharmX Corporation's board of directors awarded Daniels a non-qualified stock option to purchase 225,000 shares of BioPharmX Corporation's common stock at an exercise price of $1.09. Her stock option will vest at the rate of 25% of the shares on (i) the first anniversary of the commencement of Daniels' employment with the company, and then one forty-eighth (1/48) of the shares monthly thereafter, subject to Daniels' continued service with BioPharmX. The stock option was granted as an inducement material to Daniels' employment in accordance with Section 711(a) of the NYSE MKT Company Guide.
About BioPharmŪ Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company focused on dermatology, with products serving the women's health market. The company seeks to provide products through proprietary platform technologies for prescription, over-the-counter ("OTC"), and supplement applications. To learn more about BioPharmX, visit www.BioPharmX.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.